On the other hand, pericytes have been shown to protect endothelial cells from anti-angiogenic drug (i.e. bevacizumab), and therefore combination treatment with PDGFRβ tyrosine kinase inhibitor (i.e. eliminating PDGFRβ positive pericytes) and VEGF inhibition more efficiently block tumor angiogenesis than anti-VEGF therapy alone in several animal models13,14. The gene discussed is VEGFA; the disease is neoplasm.